Report library

MedTech analysis
Special bundles
Strategy analysis
Strategy analysis
Disease analysis
Company analysis
Drug analysis
MedTech analysis

Text search

Sort by Random

Display 15 Products per page

Adcirca
Read More
Launching after Revatio, Adcirca became the second-to-market PDE5 inhibitor upon its approval in major markets in 2009. Inhibiting the PDE5 enzyme enhances the effect of the endogenous vasodilator, nitric oxide (NO).
October 29, 2018
Find out more
Biopsy Devices Market

$4,750.00

Symptomatic benign prostatic hyperplasia (BPH) and prostatitis affect more than 100 million men worldwide, lowering quality of life with painful symptoms that can be difficult to manage.
May 2, 2017
Find out more
Vraylar
Read More
Vraylar (cariprazine; Gedeon Richter/Allergan/Mitsubishi Tanabe) is a novel atypical antipsychotic with partial agonistic activity at D2 and D3 receptors, and selectivity for the D3 receptor.
March 29, 2018
Find out more
Squalamine
Read More
Ohr Pharmaceutical will aim to make squalamine (OHR-102) the first topical treatment approved for

wet age-related macular degeneration (AMD)
September 8, 2017
Find out more
Tykerb
Read More
Tykerb (lapatinib; Novartis) is an orally available EGFR (epidermal growth factor receptor) and human epidermal growth factor receptor 2 (HER2) dual tyrosine kinase inhibitor.
March 9, 2015
Find out more
Renal Cell Carcinoma KOL Interview – UK

$599.00

This interview with a UK-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for renal cell carcinoma. Disease stratifications by staging and origin of the primary tumor, as well as unmet needs, are also discussed. Key therapies highlighted include Opdivo, Cabometyx, Keytruda, Inlyta, Lenvima, and Tecentriq.
May 13, 2020
Find out more
European Markets for Prosthetic Vascular Grafts

$3,850.00

Prosthetic vascular grafts, made of synthetic or biological materials, are used to bypass or replace segments of blood vessels in kidney failure patients requiring hemodialysis access as well as those undergoing treatment for aneurysms or vascular occlusions.
July 1, 2013
Find out more
PT010
Read More
PT010’s (budesonide/glycopyrronium/formoterol; AstraZeneca) potential to simplify the management of chronic obstructive pulmonary disease (COPD) for patients with advanced disease boosts its overall clinical score.
July 31, 2018
Find out more
Disease Analysis: Meningococcal Vaccines
Read More
Meningococcal meningitis is caused by the bacteria Neisseria meningitidis, which causes a serious infection to the lining surrounding the brain and spinal cord. In all, 12 known serogroups of Neisseria meningitidis have been identified, six of which (A, B, C, W, X, and Y) can cause epidemics. The Centers for Disease Control and Prevention (CDC) has reported around 1 in 10 people are asymptomatic carriers of the bacteria.
January 10, 2022
Find out more
Company Analysis: Gilead

$3,000.00

PharmaVitae explores Gilead’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts. The full company profile encompasses analysis on corporate strategy, portfolio analysis, pipeline potential, and financial performance.
January 25, 2021
Find out more
Advate
Read More
The recombinant factor VIII (rfVIII) therapy Advate was initially developed by Baxter and then marketed by the pharmaceutical spin-off Baxalta, which is now part of Shire. Advate is the first third-generation rfVIII, and is a follow-on product to Shire’s Recombinate.
May 4, 2018
Find out more
ISPOR Europe 2018 Whitepaper

$2,995.00

Datamonitor Healthcare attended the ISPOR 21st Annual European Congress held in Barcelona on 10–14 November. Here, we present some of the hot topics discussed at the event.

November 23, 2018
Find out more
Market Spotlight: Amyloidosis

$1,318.00

This Market Spotlight report covers the Amyloidosis market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, licensing and acquisition deals, and a 10-year disease incidence forecast, as well as presenting drug-specific revenue forecasts.
April 14, 2022
Find out more
US Neurointerventional Devices Market

$4,750.00

Neurointerventional radiology/surgery, or neurovascular intervention, is a relatively new medical specialty employing minimally invasive endovascular techniques to treat vascular diseases of the brain. Neurointerventional devices, which contributed sales of more than $870m in the US in 2015, involve a variety of standard and application-specific transcatheter tools and techniques for the treatment of cerebrovascular pathologies (such as aneurysms, arteriovenous malformations [AVMs], and acute and chronic thromboembolic and atherosclerotic occlusions) that prompt clinically significant distortions of cerebral blood flow and carry a high risk of catastrophic breakdowns of cerebrovascular circulation manifested by hemorrhagic or ischemic stroke.
September 21, 2016
Find out more
R&D Trends 2016

$2,995.00

Over the nine-year period from 2006 to 2014, the Big Pharma, Mid Pharma, and Japan Pharma peer sets collectively spent an annual average of $94bn on R&D of pharmaceuticals, with spending growing at a compound annual growth rate (CAGR) of 6%.
October 17, 2016
Find out more

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Call Back

Name

Email *

Company name *

Phone number *